

IN THE SPECIFICATION:

Please amend the specification as follows:

At page 1, line 6, please delete "09/____,____" and substitute therefor --09/524,325--.

At page 1, line 7, please delete "pending" and substitute therefor --U.S. Patent No. 6,140,467--.

At page 55, line 20, after "site," please insert --(SEQ ID NOS:7-8)--.

At page 62, line 12, after "Primers," please insert --(SEQ ID NOS:9-16)--.

IN THE CLAIMS:

Please amend the claims as follows:

- B1
-
26. (Amended) A method for inhibiting a p30 polypeptide-mediated cellular response comprising
- (a) providing [an] a composition that binds to a p30 polypeptide, HVEM or LTβR and that inhibits binding of a cell surface expressed p30 polypeptide to a cell surface expressed HVEM or LTβR, said p30 polypeptide having an apparent molecular weight of about 30kDa as determined by SDS-PAGE and an isoelectric charge (pI) of between about pI 7 to about pI 8.5 and that binds HVEM or LTβR; and
- (b) contacting the cell expressing the cell surface expressed p30 polypeptide or the cell surface expressed HVEM or LTβR with an amount of the composition sufficient to inhibit a p30 polypeptide-mediated cellular response.
-
27. The method of claim 26, wherein the cell is contacted with the composition *in vivo*.
28. The method of claim 26, wherein the inhibited p30 polypeptide-mediated cellular response comprises inhibition of a lymphocyte cellular response.
29. The method of claim 28, wherein the inhibited lymphocyte response is lymphocyte proliferation.
30. The method of claim 28, wherein the inhibited lymphocyte is a pathogenic effector cell.
31. The method of claim 28, wherein the inhibited lymphocyte response modulates a T or a B lymphoma or leukemia or an autoimmune disease.
32. The method of claim 31, wherein the autoimmune disease is rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus or myasthenia gravis.